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Background: Transverse myelitis (TM) is an immune-mediated disorder of the spinal cord that affects
adults and children and that causes motor, sensory and autonomic dysfunction. There is a prolonged
recovery phase, which may continue for many years. Neuromyelitis optica (NMO) is an uncommon
relapsing inflammatory central nervous system condition in which TM can be the first presenting symptom.
As TM and NMO affect many patients in the prime of their working life, the disorder can impose a
significant demand on health resources. There are currently no robust controlled trials in children or
adults to inform the optimal treatment of TM. However, treatment with intravenous immunoglobulin
(IVIG) is being effectively used in the management of a range of neurological conditions. Although other
interventions such as plasma exchange (PLEX) in addition to intravenous (IV) methylprednisolone therapy
can be beneficial in TM, PLEX is costly and technically challenging to deliver in the acute setting. IVIG is
more readily accessible and less costly.
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Objective: To evaluate whether additional and early treatment with IVIG is of extra benefit in TM compared
with standard therapy with IV steroids.
Design: A multicentre, single-blind, parallel-group randomised controlled trial of IVIG compared with
standard therapy for the treatment of TM in adults and children.
Participants: Patients aged ≥ 1 year diagnosed with either acute first-onset TM or first presentation of
NMO. Target recruitment was 170 participants (85 participants per arm).
Interventions: Participants were randomised 1 : 1 to treatment with IV methylprednisolone only or
treatment with IV methylprednisolone plus 2 g/kg of IVIG in divided doses within 5 days of the first
commencement of steroid therapy.
Main outcome measures: Primary outcome measure – American Spinal Injury Association (ASIA)
Impairment Scale at 6 months post randomisation, with a good outcome defined by a two-grade change.
Secondary and tertiary outcome measures – ASIA motor and sensory scales, Expanded Disability Status
Scale, health outcome, quality of life, Client Service Receipt Inventory and International Spinal Cord Injury
Pain, Bladder and Bowel Basic Data Sets.
Results: In total, 26 participants were screened and two were randomised into the study. With the limited
sample size, treatment effect could not be determined. However, we identified barriers to accrual that
included strict inclusion criteria, the short enrolment window, challenges associated with the use of the
ASIA Impairment Scale as an outcome measure and estimation of the incidence of TM.
Conclusions: The study did not reach the end point and the effect of IVIG in TM/NMO could not be
determined. Investigators should be aware of the potential challenges associated with carrying out a rare
disease trial with a short enrolment window. The study question is one that still necessitates investigation.
Preliminary work to ameliorate the effect of the barriers encountered in this study is vital.
Trial registration: EudraCT 2014-002335-34, ClinicalTrials.gov NCT02398994 and Current Controlled
Trials ISRCTN12127581.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 21, No. 31. See the NIHR Journals Library website
for further project information. Funding was also received from Biotest AG, Germany (supply of IVIG) and
the Transverse Myelitis Society (excess research cost to facilitate study initiation).
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Plain English summary
T ransverse myelitis (TM) is a rare immune disorder that affects the spinal cord. Patients who develop TMcan quickly lose the feeling in and the ability to move lower parts of the body (paraplegia). Additionally,
the upper body can also be affected (tetraplegia). TM can affect people at any age and can have a
significant impact on quality of life and place a large demand on health resources.
Although immune treatments such as steroids, intravenous immunoglobulin (IVIG) and plasma exchange
are being used to treat TM, until now, no high-quality trial has been conducted to measure how effective
these treatments are when utilised individually or in combination. Therefore, this randomised controlled
trial was designed to see whether or not newly diagnosed TM patients would benefit from early treatment
with IVIG if added to steroid therapy, which we expect all patients to receive. We measured the effect of
treatment using the American Spinal Injury Association (ASIA) Impairment Scale, an outcome measure that
has been validated in spinal injury research, and using evaluators who were not aware of the treatment
that patients had received (single blind).
After 1 year, despite 15 centres recruiting across the UK, only two patients were randomised. The key
reasons for this include the strict inclusion criteria, the short enrolment window, the challenges associated
with the use of the ASIA Impairment Scale as the primary outcome measure, an inaccurate estimation of
the incidence of TM and the spectrum of severity within the target population and inadequate funding
provision for some sites. As 170 cases were required to determine a statistically significant effect of
treatment, the study was closed early as this end point would not have been realistically achieved.
However, we are now aware of important factors that need to be addressed when undertaking a trial in
TM or an allied rare condition.
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Scientific summary
Background
Transverse myelitis (TM) is a rare inflammatory disorder of the spinal cord affecting approximately
350 children and adults annually in the UK. TM attacks usually develop over 24 hours and, in some cases,
can progress rapidly to a potentially devastating and sometimes life-threatening condition. The severity
of symptoms depends on the spinal cord level affected, with patients with high cervical lesions often
requiring intensive care support to maintain respiratory function. Patients can recover fully from TM but a
large number are left with significant disability. Among patients who recover, recovery occurs within weeks
of the onset of symptoms and is most rapid during the first 3–6 months, although further improvement
may be seen for up to 2–4 years.
A proportion of patients initially diagnosed with TM will subsequently relapse, often with the involvement
of other parts of the central nervous system (CNS), and may often be diagnosed with either multiple
sclerosis or neuromyelitis optica (NMO). NMO is a relapsing subset of TM, usually caused by antibodies to
aquaporin 4. Clinically, patients have recurrent episodes of predominantly myelitis and optic neuritis. Initial
presentation may be with myelitis alone, making it clinically and radiologically indistinguishable from TM,
and patients are thus subjected to the same acute therapeutic strategies.
No robust controlled trials have been carried out in children or adults to inform the optimal treatment of
TM. Standard treatment with intravenous methylprednisolone (IVMP) is based on class IV evidence that it
shortens the relapse duration and speeds recovery in exacerbations of adult multiple sclerosis. Given the
disease severity and poor outcomes, plasma exchange (PLEX) has been used in addition to standard therapy
with some effect. However, PLEX is not universally available in the NHS, particularly at short notice and at
weekends, and can be technically difficult and costly to administer. Randomised controlled trials (RCTs)
have demonstrated intravenous immunoglobulin (IVIG) efficacy in a number of neurological conditions. In
steroid-unresponsive CNS demyelination, IVIG is often used, although supporting data are limited to small
case series and single case reports. IVIG appears to inhibit complement binding, neutralise pathogenic
cytokines, down-regulate antibody production, enhance remyelination and modulate phagocytosis and T-cell
function. The majority of these factors are common across inflammatory disorders of the CNS, including TM,
providing a strong rationale for its use. Its availability, ease of administration, familiarity and safety also make
IVIG an attractive option in the acute setting.
Objective
The primary aim of this study was to evaluate whether or not additional, and early, treatment with IVIG is
of extra benefit in TM compared with the current standard therapy of IVMP.
The secondary objectives were to investigate the following potential benefits:
l The clinical and para-clinical data collected from patients will provide a robust resource and platform
for other clinical studies, including the identification of early predictors of poor outcome.
l Biobanked samples from patients recruited to the study will be collected and used for carefully designed
biological studies by a consortium of established basic science researchers in the field.
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Method
The randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the
treatment of transverse myelitis in adults and children (STRIVE) study was a multicentre, single-blind,
parallel-group RCT with follow-up visits at 3, 6 and 12 months following randomisation.
Patients were considered for recruitment if they were aged ≥ 1 year, had been diagnosed with either acute
first-onset TM or NMO, had an American Spinal Injury Association (ASIA) Impairment Scale score from A
to C (categories range from A to E, with category E describing normal function and category A describing
complete lack of motor and sensory function below the level of injury) and were within 5 days of
commencing steroid treatment.
Randomisation was 1 : 1 to treatment with IVMP (control arm) or IVMP plus 2 g/kg of IVIG in divided doses
(treatment arm). The sample size calculation yielded a target sample size of 170 participants (85 participants
per arm).
The primary outcome was assessed at 6 months post randomisation, with a good outcome defined by a
two-grade change in ASIA Impairment Scale score.
The following additional outcomes were measured:
l secondary end-point measures:
¢ ASIA motor scale (0–100) and ASIA sensory scale (0–112) at 3, 6 and 12 months post randomisation
¢ Kurtzke Expanded Disability Status Scale assessment using Neurostatus scoring at 3, 6 and
12 months
¢ EuroQol-5 Dimensions youth version at 3, 6 and 12 months for patients aged 8–12 years
(at presentation)
¢ EQ-5D five-level version at 3, 6 and 12 months for patients aged ≥ 13 years (at presentation)
¢ International Spinal Cord Injury Quality of Life (SCI-QOL) Basic Data Set at 3, 6 and 12 months for
patients aged ≥ 13 years (at presentation)
¢ Client Service Receipt Inventory at 3, 6 and 12 months
l tertiary end-point measures:
¢ patients aged ≥ 13 years (at presentation): International SCI-QOL, Pain, Bladder and Bowel Function
Basic Data Set at 6 and 12 months post randomisation
¢ patients aged 2–4 years (at presentation): Paediatric Quality of Life Inventory (PedsQL™) Parent
Report for Toddlers at 6 and 12 months
¢ patients aged 5–7 years (at presentation): PedsQL Parent Report for Young Children at 6 and 12 months
¢ patients aged ≥ 13 years (at presentation): International SCI-QOL Pain Basic Data Set at 6 and
12 months.
Results
Of the 28 patients screened for eligibility, two were randomised into the study between 4 March 2015 and
8 February 2016, precluding any statistical analysis of the data, and, consequently, any differences in treatment
outcomes between the two study arms could not be determined. However, we identified multiple barriers to
accrual into the study. These included the strict inclusion criteria, the short enrolment window, challenges
associated with the use of the ASIA Impairment Scale as the primary outcome measure, an inaccurate
estimation of the incidence of TM and the spectrum of severity within the target population and the variability
of research funding of individual sites.
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Conclusions
The clinical and health economic impacts of the use of IVIG in addition to standard therapy with IVMP in the
treatment of adults and children with TM/NMO could not be determined in the study. As the study question
is crucial to inform the acute treatment of TM/NMO patients, and thus one that necessitates further
investigation, we recommend additional research to establish the incidence and the spectrum of severity
of the disorder within the intended study population, alongside evaluating the utility of alternative primary
outcome measures such as the ASIA motor score and other patient-derived outcome measures. The success
of future intervention trials in TM will be contingent on being able to overcome recruitment barriers
identified in this study, which may have broader implications for investigators embarking on similar studies in
other rare disorders.
Trial registration
This study is registered as EudraCT 2014-002335-34, ClinicalTrials.gov NCT02398994 and Current
Controlled Trials ISRCTN12127581.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research, Biotest AG, Germany (supply of IVIG) and the Transverse Myelitis Society
(excess research cost to facilitate study initiation).
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Chapter 1 Introduction
Background
Transverse myelitis (TM) is an immune-mediated disorder of the spinal cord affecting children and adults
and is usually characterised by a rapid onset of paraplegia or tetraplegia, loss of sensation and sphincter
disturbance.1 Histologically, TM is characterised by spinal cord immune cellular infiltration, with pathogenesis
mediated by a variety of immunological mechanisms.1 Attacks usually develop over 24 hours and, in some
cases, can progress rapidly to a potentially devastating and life-threatening condition. The severity of
symptoms depends on the spinal cord level affected, with patients with high cervical lesions often requiring
intensive care support to maintain respiratory function. Patients can recover fully from TM but a large number
are left with significant disabilities. Recovery occurs within weeks of the onset of symptoms and is most rapid
during the first 3–6 months, although further improvement may be seen for up to 2–4 years.2
Diagnostic criteria for TM were established by the Transverse Myelitis Consortium Working Group in 2002.3
A proportion of patients initially diagnosed with TM will subsequently relapse, often with the involvement
of other parts of the central nervous system (CNS), and may then be diagnosed with either multiple
sclerosis (MS) or neuromyelitis optica (NMO). NMO is a relapsing subset of TM, caused by antibodies to
aquaporin 4 (AQP4).4 Clinically, patients have predominantly recurrent episodes of myelitis and optic
neuritis. Neurodisability accrues with progressive relapses. Initial presentation may be with myelitis alone,
making it clinically and radiologically indistinguishable from TM, and patients are thus subjected to the
same acute therapeutic strategies.
The precise number of patients who make a full recovery from TM remains unclear. Studies carried out
before the development of the Transverse Myelitis Consortium Working Group criteria may have included
patients with a wider range of myelopathies, such as spinal cord infarction,5 or may reflect the greater
severity of cases seen at tertiary referral centres such as the Johns Hopkins Transverse Myelitis Centre,6
where up to 20% of patients are reported to make a good recovery. Currently, the only report to reliably
inform on the outcome of adult-onset TM is a retrospective French multicentre study applying Transverse
Myelitis Consortium Working Group criteria, with 36% of patients with TM having a poor prognosis,
defined by death or non-ambulating.7 Approximately half of children with TM make a good recovery.8
Hence, the majority of adults and children presenting with TM have either a fair outcome (functional and
ambulatory but with varying degrees of spasticity, urgency and/or constipation and some sensory signs) or
a poor outcome (remaining completely or largely unable to walk, having at best partial sphincter control
and being left with severe sensory deficits).2 These outcomes have a huge burden on patients and their
carers. With conservative estimates of the incidence of TM in the UK being 350 cases per year (based on
an incidence of three to seven cases per million),9,10 this clearly imposes a significant cumulative demand
on health resources in the UK. Moreover, many patients are affected when they are in the prime of their
working life, thus resulting in a loss of productivity and imposing a further financial impact on the country.
Importantly, strategies to reduce disability in patients are urgently required, but there have been no robust
randomised controlled trials (RCTs) carried out in children or adults to inform on the optimal treatment of
TM. The current clinical consensus is derived from data that are extrapolated mainly from class IV evidence
from case series or clinical trials on the treatment of exacerbations of adult MS.9–12 In adults, this evidence
suggests that treatment of relapses with intravenous methylprednisolone (IVMP) shortens relapse duration
and speeds up recovery. It is on this evidence that the current standard therapy for TM has been based,
with both children and adults treated with high-dose intravenous (IV) steroids for 3–7 days to reduce
inflammation, hasten recovery and restore neurological function.13
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Although IV steroids are now the most common treatment for TM, there are other interventions that
have proved effective in aiding recovery, but which are not routinely applied. In a retrospective analysis of
122 adults with TM, acute therapies given at one centre between 2001 and 2005 were evaluated, with
the finding that some patients benefited from the addition of plasma exchange (PLEX) to IVMP.11 The
efficacy of PLEX was also demonstrated in a small RCT in adults with acute CNS demyelination (including
four patients with TM), in whom steroids had failed to induce a remission of symptoms.14 However,
administering PLEX is technically difficult and costly, making it challenging to deliver within the NHS and
resulting in it not being universally available.
Treatment with intravenous immunoglobulin (IVIG) is also used increasingly in the management of a range of
neurological conditions and its efficacy has been clearly established in RCTs for a handful of these conditions.15
In adults and children with CNS demyelination who do not respond to steroids, IVIG is often used, although
supporting data are limited to small case series and single case reports.16,17 The most relevant actions of IVIG
in the therapy of neurological diseases include (1) the inhibition of complement binding, (2) the neutralisation
of pathogenic cytokines, (3) the down-regulation of antibody production and (4) the modulation of Fc-receptor-
mediated phagocytosis. Additional actions include the modulation of T-cell function and the enhancement
of remyelination.18 The majority of these factors are common across inflammatory disorders of the CNS,
including TM,19 providing a strong rationale for the use of IVIG in the management of TM. In addition, IVIG is
cost-effective compared with PLEX and more readily accessible.
We aimed to conduct a multicentre, single-blind, parallel-group RCT to generate evidence to inform clinical
and health economic decisions with regard to IVIG use in adults and children with TM.
Risks and benefits
Risks
This study included adults and children. As treatments in both arms of the trial are already used in current
clinical practice, those participating faced almost no additional risk beyond what they would experience in
treatment outside the trial.
Benefits
Interventions to reduce disability in patients are urgently required. The current management recommendation
is largely based on expert opinion,13 as there have been no robust RCTs on the treatment of TM in children or
adults to inform on the optimal treatment of TM. This trial aimed to evaluate whether or not IVIG would be
beneficial in the management of TM.
Study aim
The randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the
treatment of transverse myelitis in adults and children (STRIVE) study was a multicentre, single-blind,
parallel-group RCT aimed at generating evidence to inform clinical and health economic decisions
regarding IVIG use in adults and children with TM.
The primary objective was to evaluate whether or not additional, and early, treatment with IVIG is of extra
benefit in TM compared with current standard therapy with IV steroids.
The secondary objectives were to investigate the following potential benefits:
l The clinical and para-clinical data collected from patients will provide a robust resource and platform
for other clinical studies, including the identification of early predictors of poor outcome.
l Biobanked samples from patients recruited to the study will be collected and used for carefully
designed biological studies by a consortium of established basic science researchers in the field.
INTRODUCTION
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Chapter 2 Methods and materials
Trial design
This was a UK, multicentre, single-blind, parallel-group RCT.
Patients randomised to the control arm were prescribed IVMP in line with local clinical practice.
Recommended dosages were as follows:
l paediatric patients: 30 mg/kg or 500 mg/m2 capped to a maximum dose of 1 g/day for 5 days
l adult patients: 1 g/day for 5 days.
Patients in the intervention arm received the above standard therapy plus additional IVIG:
l adults: 2 g/kg administered in five divided doses
l children > 41.2 kg: 2 g/kg administered as for adults
l children ≤ 41.2 kg: 2 g/kg administered in two divided doses.
Although IVIG dosing does not need to be administered over consecutive days, it must be administered in
accordance with the dosing schedule (see Appendix 1).
Patients could be recruited and randomised up to 5 days from the date of first commencing steroid
therapy or up to 21 days from the onset of symptoms (if definitely known).
In patients who did not respond to standard IVMP treatment or adjunctive treatment with IVIG, rescue
therapy, such as PLEX, would be instituted.
If PLEX was administered it might attenuate the treatment effect of IVIG and, indeed, might have a
treatment effect of its own. Guidance parameters were set out to define and standardise the PLEX regime
as follows:
l treatment failure would be considered if no improvement was seen or if deterioration occurred after
14 days from presentation or 5 days after completion of either treatment arm
l complete PLEX treatment would consist of at least five cycles, with at least 75% of plasma volume
exchanged in each cycle, with a 24- to 48-hour interval between each cycle
l an extra course of IVMP may be given by physicians, often during the lag phase from the decision to
proceed with rescue therapy to its initiation (usually 5–7 days).
End-point measures
Primary end-point measure
The primary outcome measure was the change in American Spinal Injury Association (ASIA) Impairment
Scale score20 (categories range from A to E, with category E describing normal function and category A
describing complete lack of motor and sensory function below the level of injury) from baseline (just prior to
randomisation) to 6 months post randomisation, with an improvement of two grades being defined as a
good outcome.
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Secondary end-point measures
l ASIA motor scale (0–100) and sensory scale (0–112) scores21 at 3, 6 and 12 months post randomisation.
l Kurtzke Expanded Disability Status Scale (EDSS) score,22 measured by Neurostatus scoring, at 3, 6 and
12 months.
l EuroQol-5 Dimensions youth version (EQ-5D-Y) score23 at 3, 6 and 12 months for patients aged
8–12 years (at presentation).
l EQ-5D five-level version (EQ-5D-5L) score24 at 3, 6 and 12 months for patients aged ≥ 13 years
(at presentation).
l International Spinal Cord Injury Quality of Life (SCI-QOL) Basic Data Set25 at 3, 6 and 12 months for
patients aged ≥ 13 years (at presentation).
l Client Service Receipt Inventory (CSRI)26 at 3, 6 and 12 months.
Tertiary end-point measures
l International SCI-QOL, Pain, Bladder and Bowel Function Basic Data Sets27,28 at 6 and 12 months post
randomisation for patients aged ≥ 13 years (at presentation).
l Paediatric Quality of Life Inventory (PedsQL™) Parent Report for Toddlers29 at 6 and 12 months for
patients aged 2–4 years (at presentation).
l PedsQL (Parent Report for Young Children30) at 6 and 12 months for patients aged 5–7 years of age
(at presentation).
l International SCI-QOL Pain Basic Data Set31 at 6 and 12 months for patients aged ≥ 13 years
(at presentation).
The overall flow of study participants from admission through to randomisation and the final visit is
summarised in Figure 1.
Study subjects
Participants were individuals who met the eligibility criteria and diagnostic algorithm (see Appendix 2) and
who lived in the catchment area of participating tertiary neurology centres (although neurologists could
also recruit patients at district general hospitals or from rapid general practitioner referrals). Eligibility for
the study was determined using the following criteria.
Inclusion criteria
Patients were eligible for inclusion in the trial if, on presentation, they:
l Were aged ≥ 1 year.
l Had been diagnosed with either acute first-onset TM or a first presentation of NMO. [The Transverse
Myelitis Consortium Working Group 2002 criteria for probable TM were used.3 Hence, following clinical
and radiological exclusion of a compressive myelopathy, a patient will be diagnosed with TM if he or she
meets all of the following criteria: sensory, motor or autonomic dysfunction attributable to spinal cord
disease; bilateral signs and/or symptoms (not necessarily symmetrical); clearly defined sensory level (except
in young children aged < 5 years when this is difficult to evaluate); lack of brain magnetic resonance
imaging (MRI) criteria consistent with MS (McDonald 2010 space criteria); and progression to nadir
between 4 hours and 21 days. Patients with definite modified NMO should meet the following criteria:32
absolute criteria – optic neuritis and acute myelitis (both) – plus two out of three supportive criteria – brain
MRI not meeting criteria for MS at disease onset, spinal cord MRI with contiguous T2-weighted signal
abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the
spinal cord, and AQP4 seropositive status.]
l Had an ASIA impairment score of A–C.
l Had commenced steroid treatment but would be randomised no later than 5 days after commencing
treatment and, if definitely known, no later than 21 days from the onset of symptoms.
l Gave assent (< 16 years)/consent to participate in the trial.
METHODS AND MATERIALS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
Exclusion criteria
Patients were excluded if they showed evidence of one or more of the following:
l contraindication to IVIG as stated in the product Summary of Product Characteristics (SmPC) or
receiving IVIG for other reasons
l previously known systemic autoimmune disease (e.g. systemic lupus erythematosus) or any evidence of
systemic inflammation during the current presentation
l direct infectious aetiology (e.g. varicella zoster)
Admission to tertiary centre 
via A&E/GP rapid referral/feeder 
hospital with suspected TM+/–NMO
Patients consented/assented
Eligible patients randomised to 
treatment arms 1 : 1
Follow-up 1 (3 months post randomisation)
Clinic visit with study physician/research nurse/physiotherapist – CRFs for 3-month follow-up completed
Follow-up 2 (6 months post randomisation)
Clinic visit with study physician/research nurse/physiotherapist – CRFs for 6-month follow-up completed
Sample taken for biobanking
Follow-up 3 (12 months post randomisation)
Clinic visit with study physician/research nurse/physiotherapist – CRFs for 12-month follow-up completed
If condition deteriorates
rescue therapy initiated:
(e.g. five cycles of PLEX
over 10 days)
Control arm
Patients receive treatment with 
IVMP 
for a 5-day period 
Neurological examination 
and ASIA score on discharge
Intervention arm
Patients receive treatment with 
IVMP plus IVIG 
for a 2- or 5-day period 
Neurological examination and 
ASIA score on discharge
Screening by clinical trial staff 
using diagnostic algorithm and 
investigation protocol – PIS given 
to eligible patients or carers
Patients who do not
meet criteria/receive 
different diagnosis will 
not be recruited and will 
be placed on appropriate 
treatment path
Baseline CRFs completed/neurological
examination/ASIA score taken/MRI cervical 
cord (TM) and AQP4 antibody testing
(NMO)/sample taken for biobanking
FIGURE 1 Participant flow chart. A&E, accident and emergency; CRF, case report form; GP, general practitioner;
MRI, magnetic resonance imaging; PIS, patient information sheet.
DOI: 10.3310/hta21310 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 31
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Absoud et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
l previous episode of CNS inflammatory demyelination
l acute disseminated encephalomyelitis
l other causes of myelopathy not thought to be caused by myelitis (e.g. nutritional, ischaemic, tumour)
l other disease that would interfere with the assessment of the outcome measures
l known pregnancy
l circumstances that would prevent follow-up for 12 months.
Spinal cord inflammation demonstrated by cerebrospinal fluid (CSF) pleocytosis or an elevated immunoglobulin
G (IgG) index or gadolinium-enhanced MRI is supportive of an inflammatory aetiology but was not essential for
inclusion/exclusion. Individuals with myelitis underwent testing for AQP4 antibodies, as NMO can present as
isolated TM. In addition, patients received investigations that were clinically indicated to identify specific
non-inflammatory aetiologies.
Sample size
In recognition of TM as a rare condition, the power analysis took into account the inclusion of a futility
analysis to be undertaken after recruitment of one-third of the target sample. We assumed that the
proportion of participants showing a two-grade improvement (or greater) on the ASIA Impairment scale
would be approximately 0.5 (50%) in the control arm and a minimum of 0.75 (75%) in the intervention
arm. The sample size calculation was based on the conservative assumption of no correlation between
repeated measures.
Randomised 1 : 1, the primary intention-to-treat (ITT) analyses would compare 76 treatment and 76 control
patients on the ASIA classification scale at 6 months post randomisation. Based on comparing the difference
in the number of successes among the treatment patients and the control patients, the SAS program sample
size chi procedure (version 9.22; SAS Institute Inc., Cary, NC, USA) examines all 772 possible trial outcomes
under the null and alternative hypotheses. The possible outcomes are then arranged in descending order and
cumulative probabilities for every possible value from 76 to –76 are computed. Using a critical value that
maintains the tail probability at 0.02355 under the null hypothesis, the probability under the alternative
hypothesis is 0.9034. The study thus had 90% power for a two-tailed test with α = 0.05.
The sample size was inflated for attrition, based on our experience and the study design; to minimise any
loss to follow-up, we estimated 10% attrition. This would require recruiting a sample size of 152/0.90 = 170
(85 participants per arm).
The ASIA total motor score (0–100) was a secondary outcome. There is little evidence in acute TM to
summarise this in terms of variance, mean and correlation. The Stata® function sampsi (version 12;
StataCorp LP, College Station, TX, USA) indicated that, using analysis of covariance, with a baseline to
end-point correlation of 0.6, the study would have 87% power to detect a difference between the control
arm and the treatment arm of a medium to large effect size of 0.4. Such a difference would be of clinical
significance.
Randomisation
Treatment allocation was to be stratified at randomisation by service type (adult or child), using stratified
block randomisation; the block would randomly vary in size. Participants were randomised 1 : 1 to
treatment.
Withdrawal
Patients (or their parents/guardians) had the right to withdraw from the study at any time for any reason.
The investigators also had the right to withdraw patients from the study drug in the event of intercurrent
illness, adverse events (AEs), serious adverse events (SAEs) and suspected unexpected serious adverse
reactions, subsequent evidence of a different aetiology, protocol violations, cure or for administrative or
other reasons. Participants who either wished to or had to discontinue study medication would be returned
to standard care through their supervising physician, but would continue to provide study-specific data at
METHODS AND MATERIALS
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follow-up visits at 3, 6 and 12 months. It was understood that an excessive rate of withdrawals could
jeopardise randomisation outcomes and render the study results uninterpretable; therefore, unnecessary
withdrawal of patients was to be avoided. If a patient had decided to withdraw from the study, all efforts
would have been made to report the reason for withdrawal as thoroughly as possible.
Study data
The study data were managed as previously described in the published trial protocol.33
Data management
Data were managed using the InferMed MACRO database system (version 4; Elsevier, Amsterdam,
the Netherlands). This system is regulatory compliant.34–36 An electronic case report form (eCRF) was
created using the InferMed MACRO system in collaboration with the trial statisticians and the chief
investigator and was maintained by the King’s Clinical Trials Unit (KCTU). It was hosted on a secure
dedicated server within King’s College London and source data were entered by authorised staff onto the
eCRF with a full audit trail.
Database passwords
Database access was strictly restricted through the use of passwords provided to authorised members of
the research team. The chief investigator or site delegate requested access from the KCTU. If a new staff
member joined the study, a personalised username and password were requested through the chief
investigator or site delegate.
Identifiable data
All participant contact information was stored within the recruiting NHS site, with restricted access from
password-protected computers. Accrual data uploaded to the UK Clinical Research Network portfolio
database were anonymised and collated by the chief investigator or trial manager to the Local Clinical
Research Network. No identifiable data were entered on the eCRF or transferred to the KCTU. Participants
were identified on the study database using unique codes and initials. Each investigator maintained
accurate patient records detailing observations of each patient enrolled.
Investigational medicinal product
The investigational medicinal product (IMP) was provided as human normal immunoglobulin (Intratect®)
[100 g/l solution for infusion in a single 5-g (50-ml) or 10-g (100-ml) glass vial] by Biotest AG, Dreieich,
Germany, the marketing authorisation holder of the commercially available Intratect.
An Annex 13 clinical trial labelling exemption37 was in place and was approved by the Medicines and
Healthcare products Regulatory Agency (MHRA) for this trial. A standard pharmacy dispensing label was
applied to the IMP at the point of dispensing by the pharmacy at each investigator site.
The IMP was stored in a secure area with limited access. Site pharmacies were responsible for the safe and
appropriate storage of the IMP at their site in accordance with the manufacturer’s instructions:
l do not store above 25°C
l do not freeze
l keep the vial in the outer carton, to protect from light.
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Dosing regimen
Intravenous methylprednisolone (as sodium succinate) was administered in accordance with local clinical
guidelines. A single daily dose of 30 mg/kg or 500 mg/m2 (maximum 1 g/day) for 5 days can be used in
paediatric patients. Adult patients can receive 1 g/day for 5 days.
Patients randomised to the control arm received no additional treatment, whereas patients randomised to
the treatment arm received the above treatment plus 2 g/kg of IVIG in divided doses (see Appendix 1).
Note that IVMP (as sodium succinate) was classed as a non-IMP in this trial and was dispensed by hospital
pharmacies in accordance with their standard clinical practice.
Risks
The current risks associated with the Intratect immunoglobulin are detailed in the SmPC for Intratect
[see www.medicines.org.uk/emc/medicine/23175/SPC/intratect/ (accessed 21 March 2017)]. A summary of
these risks is provided in Appendix 3.
Compliance
Treatment with the IMP was administered under the supervision of the investigator and in a controlled
clinical environment. Therefore, full patient compliance with treatment was anticipated.
Concomitant medication
Only relevant immunomodulatory medications were recorded throughout the study.
In patients not responding to control treatment or adjunctive treatment with IVIG, rescue therapy was to
be instituted in accordance with local guidelines. In most cases, the rescue therapy of choice was PLEX
therapy. This was also to be recorded as a concomitant medication.
Confidentiality
The study staff ensured that participants’ anonymity was maintained, identifying patients by their PIN
(personal identification number) and initials only. The study complied with the Data Protection Act 1998,38
which requires data to be anonymised as soon as it is practicable to do so.
Trial sites and study duration
The study was conducted across 15 clinical sites within the UK, with an additional site acting as a participant
information centre. The first of the 15 sites was opened for recruitment on 4 March 2015, whereas the final
site received its approval to commence recruiting on 8 February 2016. Recruitment was terminated early
across all 15 recruiting sites and the single participant identification centre on 11 March 2016.
Trial procedure
Table 1 provides a summary of the trial visit schedule and the associated assessments to be carried out.
Some of the questionnaires were specific to particular age groups, with age on presentation used as
the criterion.
Blinding
Because of the technical challenges of masking IVIG from saline, the need for rapid recruitment and the
fact that follow-up would take place many months after the event using objective well-defined clinical end
points, treatment was not blinded (no placebo). The trial manager, pharmacies and those administering
treatment were not blinded to the intervention, whereas staff carrying out primary outcome assessments
at follow-up and statistical analyses were blinded.
METHODS AND MATERIALS
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TABLE 1 A summary of the trial visit schedule and associated assessments
Schedule
Time point
T0 (screening,
baseline and
prediagnosis
tests)
T1 (treatment and
discharge)
T2
(3 months)
T3
(6 months)
T4
(12 months) Ongoing
Rescue
therapya Discharge
Screening with
the diagnostic
algorithm and core
investigations
including physical
examination
✗
Patient information
and informed
consent
✗
Eligibility form ✗
Registration form ✗
Prediagnosis tests
(e.g. MRI and AQP4
testing)
✗
Randomisation ✗
Biobank samples ✗ ✗
ASIA impairment
score (A–E)
✗ ✗ ✗ ✗ P ✗
ASIA motor and
sensory scale score
✗ ✗ ✗ ✗ S ✗
Neurostatus scoring
(Kurtzke functional
systems and EDSS)
✗ ✗ ✗ S ✗
EQ-5D-Y
questionnaire
(8–12 years)
✗ ✗ S ✗
EQ-5D-5L
questionnaire
(≥ 13 years)
✗ ✗ S ✗
CSRIb ✗ S ✗
SCI-QOL Basic Data
Set (≥ 13 years)b
✗ S ✗
SCI Bladder Function
Basic Data Set
(≥ 13 years)b
T ✗
SCI Bowel Function
Basic Data Set
(≥ 13 years)b
T ✗
SCI-QOL Pain Basic
Data Set (≥ 13 years)b
T ✗
PedsQL (5–7 years)b T ✗
PedsQL (2–4 years)b T ✗
Treatment form ✗
continued
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Screening, baseline and discharge assessments were carried out in the tertiary centres by a study physician/
research nurse. Following discharge from treatment in hospital, all primary outcome assessments at follow-up
in clinic at the tertiary centre or appropriate neurology centre were carried out by a study physician/research
nurse/physiotherapist who had been blinded to treatment. For consistency, whenever possible, the same
blinded assessor was required to carry out the assessments at each time point. Although not mandatory,
secondary and tertiary outcome assessments at follow-up were to be performed by a blinded member of
staff whenever possible.
Laboratory tests
It was planned that all consenting patients would have samples taken for clinical investigations and
biobanking at baseline and at the 6-month follow-up. In cases in which samples for clinical investigations
had been taken prior to consent, any leftover material would be used for biobanking. No additional samples
would be collected unless there was a clinical indication to do so. Samples for biobanking would consist
of CSF via lumbar puncture and blood taken by venepuncture for serum, plasma, deoxyribonucleic acid,
peripheral blood mononuclear cells and ribonucleic acid (site dependent). Samples were to be stored in one
of the two biobanks (London or Cardiff). These samples would not form part of this trial but were intended
for further hypothesis-driven biological research, directed by Neil Robertson and Gavin Giovannoni (adult
medicine) and Ming Lim (paediatric medicine).
Magnetic resonance imaging sequences
As part of the routine diagnostic process for TM/NMO, brain and spinal cord MRI sequences were acquired
when possible, the results of which were in the study’s diagnostic algorithm at screening and recorded as
study data if patients entered the trial. Local protocols were in place for the acquisition of MRI sequences,
which would usually include gadolinium-enhanced sequences in the event of suspected TM/NMO.
TABLE 1 A summary of the trial visit schedule and associated assessments (continued )
Schedule
Time point
T0 (screening,
baseline and
prediagnosis
tests)
T1 (treatment and
discharge)
T2
(3 months)
T3
(6 months)
T4
(12 months) Ongoing
Rescue
therapya Discharge
Concomitant
medications
✗
Discharge form ✗
Rescue therapy form
(if needed)a
✗
Relapse form (at any
time point if needed)a
✗ ✗ ✗ ✗
AEs ✗
Study status form ✗ ✗ ✗
Withdrawal form
(at any time point)a
✗
P, primary outcome; S, secondary outcome; T, tertiary outcome.
a Rescue therapy and relapse and withdrawal forms may be necessary for only a small subset of patients.
b Patient-administered evaluation.
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To facilitate the systematic accrual of neuroimaging information it was recommended that reports included:
l the location of the lesion (which spinal cord level)
l the size of the lesion (in terms of how many vertebral segments were involved)
l whether gadolinium injection was used and, if so, whether enhancement was seen.
During the trial period, the study team was able to request anonymised patient scans provided on a
compact disc to resolve potential clinical and radiological uncertainties.
Analysis
A comprehensive statistical analysis plan was developed and a descriptive analysis (e.g. summary statistics
and plots) was to be performed to investigate the distribution of the primary outcome, that is, the ASIA
impairment score, across participants.
Statistical analysis
All analyses were to be pragmatic and follow the ITT principle, that is, patients would be analysed in the
group to which they were randomised, irrespective of treatment received, utilising all available follow-up
data from all randomised patients. Sensitivity analyses were to be used to assess the robustness of the
conclusions to missing outcome data and to departures from randomised treatment.
An interim futility analysis was scheduled to be conducted after 52 patients had provided a response
(26 in each treatment arm), with the end point being a change in the ASIA impairment score of two or
more grades 6 months after randomisation; the results were to be assessed by the Data Monitoring
Committee (DMC).
The final analysis of effectiveness was scheduled to be conducted once the trial database had closed, if the
study continued to full recruitment. The DMC was to collate effectiveness and safety data during the trial
to inform its recommendations to the Trial Steering Committee (TSC). It was planned to summarise the
main effects by intervention arm and assessment time point, with associated 95% confidence intervals.
Primary and secondary outcome analysis
The main objective of the statistical analysis was to assess the effect of IVIG on the primary outcome,
the ASIA Impairment Scale (A–E) score, at 6 months post randomisation.
The secondary clinical assessments (EDSS, continuous ASIA motor and sensory scales, SCI-QOL, Pain,
Bladder and Bowel Basic Data Sets, PedsQL, EQ-5D and CSRI) with repeated measurements were to be
analysed within a linear mixed-model framework, with generalisations of the linear mixed model utilised to
allow for outcomes with non-normal data if necessary. Those measures with one follow-up assessment
were to be evaluated with a general linear model. The statistical modelling was designed to feature the
outcome measure(s) as the dependent variable, with corresponding baseline measure(s) (if applicable),
stratification factors and treatment group featuring as covariates.
Recruitment rate, consent rate, loss to follow-up, departures from randomised treatment and the prevalence
of SAEs (specifying deaths and intensive therapy unit admissions) were to be reported as descriptive analyses
at 3, 6 and 12 months post randomisation and summarised by treatment arm over the course of the study.
The chi-squared test (Fisher’s exact test) was to be used for categorical outcomes (e.g. SAEs and mortality).
All analyses were scheduled to be repeated considering age status (adult or child) and putative biological
markers as moderators by interaction with treatment group (control or intervention), allowing estimates of
treatment effect in the subpopulations to be summarised.
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Explanatory analyses to assess the efficacy of the treatment within NMO or idiopathic TM diagnosis by
allowing for an interaction with treatment arm were to be carried out. The intracluster correlation coefficient
of the sites would have been explored by allowing for site as a random effect in the statistical modelling.
With regard to missing data for post-treatment outcomes, which would have arisen as participants
discontinued treatment or were lost to follow-up, regression analysis based on maximum likelihood and
resulting inferences would have been valid provided that the missing data-generating mechanism was
missing at random (MAR), that is, ‘missingness’ was predicted only by variables that were included in the
model, including earlier values of the outcome variables. We aimed to empirically assess whether or not
any baseline variables predict missingness and, if this was the case, we planned to condition on such
variables by including them in the statistical model. Sensitivity analyses would have been used to assess the
robustness of the conclusions to missing outcome data and to departures from randomised treatment, as
previously described by White et al.39
Futility analysis
As previously mentioned, an interim futility analysis was scheduled to be conducted after 52 patients had
provided a response, 26 in each treatment arm, with the end point being a change in the ASIA Impairment
Scale score of two or more grades at 6 months. The trial would have been terminated with the conclusion
that the new treatment was no better than the standard treatment if, based on these 52 patients, the test
statistic was less than zero. If the sample sizes were equal, this would occur if the successes under the new
treatment were fewer than those under the standard treatment. Otherwise, the trial would proceed to the
full sample size of 170 patients. The SAS program two-stage – interim – chi evaluates the design-deleting
outcomes that would correspond to futility. The tail probabilities under the null and alternative hypotheses
were 0.0228 and 0.8946, respectively. The inclusion of the futility analysis therefore represented a very
small loss of power.
The SAS program two-stage – stage 1 – chi evaluates the properties of the first stage of the design.
It showed that the probability of abandoning the study at the interim analysis was 0.4449 under the null
hypothesis and 0.0201 under the alternative hypothesis. Therefore, there was a good chance of stopping
for futility when the treatments were equivalent and a very small chance of stopping for futility when the
desired treatment effect was present (see Appendix 4 for the futility analysis plan).
Health economics
The study team aimed to develop a health economic model structure and complete a write-up of its
economic analysis within the 12 months following the end of patient data collection (i.e. 42–54 months
after the start date).
Economic analysis
Drug pricing data and primary care, secondary care and social care costs were to be calculated as
described previously.40 Costs were to be combined with the primary outcome measure in the form of
a cost-effectiveness analysis. If IVIG resulted in higher costs and a better outcome, then an incremental
cost-effectiveness ratio would be generated to show the extra cost incurred to achieve an extra unit of
improvement. Because of the uncertainty around results, it was planned that cost-effectiveness planes and
cost-effectiveness acceptability curves would be used, with bootstrapping of skewed results.
Long-term cost-effectiveness over 5-year and 10-year periods was to be calculated using a Markov model.
Response to treatment was to be classified, and transition probabilities between groups were to be derived
from 6-month and 12-month follow-up data. Costs and quality-adjusted life-years (QALYs) for each
category were to be derived from the trial data. As limited data would be available on long-term costs, we
planned to conduct both deterministic and probabilistic sensitivity analyses.
All causes of withdrawal from randomised treatment were to be reported. The chi-squared test (Fisher’s
exact test) was to be used for categorical outcomes (e.g. SAEs and mortality).
METHODS AND MATERIALS
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There would have been missing data for post-treatment outcomes as participants discontinued treatment or
were lost to follow-up. Inferences would have been valid provided that the missing data-generating
mechanism was MAR and was not predicted by any variables in the model, that is, missingness was
predicted only by variables that were included in the model.
Economic evaluation
It was planned to record the use of IVIG, IVMP, additional treatments and rescue PLEX throughout the
follow-up period, with costing carried out using drug pricing data from the British National Formulary and
the Department of Health. It was planned to record the use of primary care, secondary care and social care
at the 3-month, 6-month and 12-month follow-ups using the CSRI, with costs calculated to determine the
total cost for the control and treatment arms.
A cost-effectiveness analysis was to be performed using the primary and secondary outcome measures of
improvement in ASIA scores and the secondary outcome of QALYs with EQ-5D-Y, EQ-5D-5L and CSRI.
If IVIG results in higher costs and a better outcome, then an incremental cost-effectiveness ratio will be
generated to show the extra cost incurred to achieve an extra unit of improvement.
Ethics and approvals
This study is registered as EudraCT 2014–002335–34, ClinicalTrials.gov NCT02398994 and Current
Controlled Trials ISRCTN12127581. Research Ethics Committee approval was obtained (South Central –
Berkshire B; reference number 14/SC/1329) alongside MHRA notification.
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Chapter 3 Trial outcome and results
Over the 53 weeks of recruitment, 26 potential participants were screened for eligibility across all15 sites. Of these 26 participants, 24 were not randomised, with 23 being ineligible [48% of these
patients (n = 11/23) had symptoms considered ‘too mild’ for inclusion and the remaining 52% (n = 12/23)
were ineligible as they did not meet other inclusion criteria or met the exclusion criteria) and one patient
having a delayed referral to the primary investigator. Two participants were therefore recruited into the study
(Figure 2), one to each arm of the trial, with each participant followed up for 6 months post randomisation
prior to withdrawal from the study. The number of participants randomised into the study was significantly
below the target sample size, thus precluding any form of data analysis or detection of a significant
difference between the control arm and the treatment arm of the study.
Assessed for eligibility
(n = 26)
Randomised
(n = 2)
Excluded
(n = 24)
• Did not meet all eligibility 
   criteria, n = 23
   • Too mild, n = 11
   • Other, n = 12
• Missed, n = 1
   • Completed 5 days of steroid 
      treatment prior to referral 
      to Pl, n = 1
Allocated to IVIG
(n = 1)
• Received IVMP, n = 1
• Received IVIG, n = 1
Allocated to placebo
(n = 1)
• Received IVMP, n = 1
• Received IVIG, n = 0A
llo
ca
ti
o
n
• Completed assessment, n = 1
• Withdrew consent, n = 0
• Withdrawn from study, n = 0
• Completed assessment, n = 1
• Withdrew consent, n = 0
• Withdrawn from study, n = 0
3-
m
o
n
th
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• Completed assessment, n = 1
• Withdrew consent, n = 0
• Withdrawn from study, n = 1
• Completed assessment, n = 1
• Withdrew consent, n = 0
• Withdrawn from study, n = 1
6-
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• Completed assessment, n = 0
• Withdrew consent, n = 0
• Withdrawn from study, n = 0
• Completed assessment, n = 0
• Withdrew consent, n = 0
• Withdrawn from study, n = 0
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FIGURE 2 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram. PI, primary investigator.
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Baseline and 3-month data summary
Descriptive summarisation of both participants’ data was carried out following a lock of the study data; the
trial statistical team remained masked to treatment allocation up to this point. One patient was a white female
child aged between 10 and 15 years (student), with an unknown body mass index (BMI). This participant had
an ASIA impairment score of C prior to randomisation, meaning that motor function was preserved below
the neurological level and more than half of the key muscles below this level had a muscle grade of < 3. At
3 months post randomisation this participant had improved to an ASIA impairment score of D, meaning that
at least half of the key muscle functions below the neurological level had a muscle grade of ≥ 3. The other
participant was a white adult male aged between 60 and 65 years in full-time employment and with a BMI of
30 kg/m2. This participant had an ASIA impairment score of A prior to randomisation, meaning that no motor
or sensory function was preserved in sacral segments S4–S5. At 3 months post randomisation, this participant
had not improved. Neither participant suffered a relapse during the trial. The adult participant suffered from
two AEs during the trial, a chest infection and pressure sores, which were not related to the trial; the
paediatric participant suffered no AEs. Because of the very small sample size it is not possible to comment on
whether there is any relationship between the trial arm and any change in ASIA impairment scores.
Withdrawal
Both randomised patients remained in the trial until their second follow-up visit (6 months post
randomisation), at which point they were withdrawn from the study by the study team.
The rationale behind the termination and subsequent withdrawal was explained to both participants, both
of whom had recourse to further information.
Health economics analysis
As the trial did not recruit a sufficient number of participants, it was not possible to conduct the health
economic analysis.
Investigator (opinion leader) feedback
Following the termination of the study, the study team developed a survey that sought to both gain feedback
on the study and develop a better understanding of the reasons, in the opinion of the investigators, the study
did not recruit to target. The survey questions were sent to 13 of the 15 recruiting sites, as the remaining two
sites were those of the chief investigator and the co-investigator/project co-ordinator, both of whom were
involved in the design of the survey. Of the 13 investigators contacted, 11 responded. A summary of these
responses is provided in Table 2.
TABLE 2 Summary of the post-study survey of sites that that took part in the trial
Question
Investigator’s response (n= 11)
Agree
Neither agree
nor disagree Disagree
1. The aim and overall objective of the study was clear 11 0 0
2. The study design was simple enough to understand 10 1 0
3. All of the study procedures (including study visits at 3, 6 and 12 months
post treatment) were in line with our standard care for TM/NMO patients
6 3 2
4a. The ASIA score was an appropriate measure to use 3 4 4
TRIAL OUTCOME AND RESULTS
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TABLE 2 Summary of the post-study survey of sites that that took part in the trial (continued )
Question
Investigator’s response (n= 11)
Agree
Neither agree
nor disagree Disagree
4b. What alternative would you have considered if any? Motor component of ASIA assessment, n= 1;
EDSS, n= 2; MSFC, n= 1; assessment of
mobility, n= 1; a bespoke assessment score
validated in advance, n= 1
5. The trial offered good treatment options for TM/NMO 7 3 0
6. The trial was sufficiently pragmatic 6 2 1
7. The site was an appropriate choice for the trial 11 0 0
Investigator
1. I think addressing the study question is highly important and should be
a priority
10 1 0
2. The outcome of this study would have changed how I treat my TM patients 9 1 1
3. Within my daily workload, I believe I had enough time to allocate to
activities that the study required (both clinical and administrative)
2 2 7
4. I generally find it difficult to participate in all kinds of clinical trials
nowadays because of a lack of time
7 3 1
5. A study visit by a participant had (or would have had) an undesirable
impact on my clinic (e.g. significantly increasing the clinic time or time for
administration of the clinic)
5 3 3
6. I generally find it difficult to find time for all study visits nowadays 4 4 3
7. What in your opinion was the single most important reason this trial
failed?
‘Strict inclusion criteria’, n= 4; ‘rarity of
cases’, n= 3; ‘choice of outcome measure’,
n = 2; ‘early recognition of cases’, n= 3;
and ‘finding time to recruit patients’, n= 1
8. What would you have changed about the study? Broader eligibility criteria, n= 3; inclusion of
less severe patients, n= 5; use of different
outcome assessment, n= 5; improved
awareness among all neurologists and
engage all sites earlier, n= 3
Study set-up and recruitment
1. I was actively involved in the site feasibility discussion before the study
opened at my site
8 2 0
2. Set-up of the study felt complicated at times 5 1 4
3. All things considered, I think funding for sites for this study was not
really adequate
7 2 2
4. I found my interaction with our R&D department useful during the
set-up and administration of this study (if applicable)
7 3 1
5. I was unable to recruit because (choose as many as applicable) Strict inclusion criteria, n= 9; no cases
came to my attention, n = 5; came to
know late of case, n= 7; did not have
time, n= 0; other, n= 1
Other
1. I received as much assistance as needed from the study co-ordinating
team (trial manager, sponsors, etc.)
10 1 0
2. The study co-ordinating team could have done more to increase
awareness of the study among other clinicians or the potential patient
population
4 1 6
3. In future, I would be interested in collaborating with this team in
designing and running another study
9 2 0
MSFC, Multiple Sclerosis Functional Composite; R&D, research and development.
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Chapter 4 Discussion: lessons learned from early
closure of the trial
This study aimed to elucidate the added benefit in terms of clinical efficacy and health economicsassociated with additional and early treatment of TM with IVIG compared with the current standard
therapy of IV steroids. However, because the study under-recruited, we were unable to determine whether
or not there were any differences between the trial arms. The barriers encountered during the course of
the trial are discussed in this chapter. Other researchers planning a similar study would benefit from being
aware of these barriers and their potential impact.
Overview of the trial evolution
The first trial recruiting site received approval to start recruiting on 4 March 2015, whereas the final site to
receive its approval did so on 8 February 2016. At the point at which the study was suspended (11 March 2016),
15 sites were open to recruitment, with two sites each recruiting one subject. The TSC met on 11 March 2106,
when strategies to further improve recruitment into the study were extensively discussed. Following this
meeting, the TSC and Trial Management Group (TMG) jointly decided that further recruitment into the study
should be suspended with immediate effect. The TSC and TMG came to this decision because the study, on its
current trajectory, was unlikely to recruit to sufficient numbers to allow scientifically valid deductions to be made.
The study co-ordinating team consulted the National Institute for Health Research (NIHR) monitoring team and,
following further discussion with the respective programme directors, early termination of the study was agreed.
The need for better understanding of transverse
myelitis epidemiology
A lower than expected frequency of patient encounters is believed to be the main factor that led to the
low levels of recruitment observed in this study. The challenges associated with recruitment to rare disease
trials are not restricted to this study alone. A large-scale comparison of interventional trials (24,088 trials),
of which 2759 (11.5%) were classified as rare disease trials and 21,329 (88.5%) as non-rare disease trials,
found that rare disease trials are more likely to be terminated early (13.7%) than non-rare disease trials
(6.3%).41 The same study found that, on average, fewer patients were recruited into rare disease trials
(70.1%) than into trials of non-rare diseases (81.6%) than initially estimated. It is perhaps intuitively
understandable that, because of the uncommon nature of the disorders under study, one of the most
frequent problems faced during the conduct of rare disease trials is recruitment of the requisite number of
study subjects.41,42
The trial team were aware of the challenges associated with recruitment into rare disease trials and a prior
feasibility assessment suggested a higher frequency of patient encounters than was eventually observed.
With the yearly incidence of TM being approximately 350 cases (109 cases proportionately across the
15 open sites, based on a study team projection that 24 sites would capture 50% of cases of TM in the
UK), the relatively low rate of patient encounters reported by all sites was unexpected. Furthermore, based
on our estimated 35% recruitment rate, approximately 38 subjects could theoretically have been recruited
by the open sites per year, rather than the two actually recruited. Interestingly, although numerous
evidence (screening logs, informal discussions with recruiting site personnel and the investigator survey
responses) pointed towards a low rate of patient encounters, anonymised data provided by the TM patient
group, the Transverse Myelitis Society (TMS), showed that 61 registered members of the society reported
having been diagnosed with TM in 2015 (of whom 57 had a confirmed TM diagnosis) (Barbara Babcock,
TMS chairperson, May 2016, personal communication) (see Appendix 5). These data suggest that the
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incidence of the disease may not have been overestimated by the study team, especially as the TMS data are
likely to be an underestimate of the true incidence of TM (reflecting only the individuals who actually took
time to register with the society). However, an analysis of the geographical distribution of these subjects
indicated that more than half resided > 25 miles away from a recruiting site (see Appendix 5). This
observation points towards a level of geographical disconnect between the potential patients and the trial
sites. Additionally, although local TM cases were often referred to, or had their treatment discussed with, the
investigators involved in the trial, it is likely that some potentially eligible subjects were seen and treated
exclusively by their local physician. The study team did take steps to ensure wide dissemination of the study
among the neurology network by inclusion of the study details in the Association of British Neurologists
newsletter and conferences, with an e-mail sent to members, presentation of the study at the TMS annual
general meeting and conference, distribution of ward leaflets and admission unit posters at participating
sites and the provision of study flyers for use in district general hospitals.
The low frequency of patient encounters was further complicated by the fact that a significant proportion of
subjects who were considered for the trial were not eligible for inclusion into the study. One reason for this
may be that the investigators may not have wholly appreciated the strictness of the eligibility criteria during
the feasibility assessment. Indeed, ‘strict inclusion criteria’ was cited by 82% (n = 9/11) of respondents in the
post-trial survey as a key factor that they believed had inhibited recruitment into the study. Notably, these
inclusion criteria were mandated by the primary end point of the study, with recruited patients needing to
have at least an ASIA impairment score of C to observe at least a two-grade improvement in this scale (see
Considerations of the design of the study). This highlights the absolute necessity for further studies to establish
both the incidence and, equally as important, the severity of TM cases that are observed.
Navigating operational barriers in the set-up and running of a
rare disease trial
Although the low frequency of patient encounters primarily led to the study under-recruiting, other
barriers played an important role in complicating the study set-up and the running of the study and
ultimately the recruitment of subjects into the study. Hurdles in setting up the trial within the NHS sites,
including contract and cost negotiations, local governance and a lack of capacity of research staff (research
nurses’ and/or investigators’ competing priorities, i.e. clinical and trial commitments) led to the staggered
opening of target sites. The overall impact of this was that, at the time of the study closure, only 62.5%
(n = 15/24) of target sites were opened and recruiting. As recruitment logs were not available for sites that
failed to open (n = 9), we are not able to say what the frequency of patient encounters would have been.
The impact of this is best understood in light of the fact that the 24 originally targeted sites were assumed
to represent the neurology services that catered for approximately half of the UK population. With only
15 of these target sites open, approximately 31% of new TM/NMO cases were geographically covered.
Lack of research capacity, described as the unavailability of site research staff or co-investigators or competing
clinical priorities and commitments to other trials, played a significant role in five of the 24 target sites failing
to open. Unsurprisingly, in the survey of investigators who took part in this study, 63.6% (n = 7/11) found it
difficult to run all kinds of clinical trials at the present time because of a lack of time; 27.3% (n = 3/11) found
it neither difficult nor easy; and one investigator (9.1%) did not currently find it difficult to run clinical trials
because of a lack of time (see Appendix 6 for details).
The protracted contract negotiations and cost allocations highlight a wider issue related to differences in
health service provision within different regions, in particular the interpretation of standard of care across
different (neurology) services. For instance, although the premise of the study (which informed the funding
structure) was that most of the study activities were found within standard patient care, some of these
activities, such as the ASIA assessment, were evidently not routinely used within some neurological
services. These differences impacted not only on the ability of target sites to be opened, but also on how
DISCUSSION: LESSONS LEARNED FROM EARLY CLOSURE OF THE TRIAL
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and when sites could be authorised to commence patient recruitment. As site activation was predicated on
at least one researcher within a site being ASIA assessment trained, sites that did not routinely use this
assessment tool required a member of the research team (preferentially the principal investigator) to
undertake the training and gain competence in ASIA assessment. Moreover, competency in ASIA
assessment required online training that could take up to 6 hours. At least one site remained unopened at
the point of the study closure despite having all other approvals in place and having already had their site
initiation visit, as the primary investigator was unable to complete the ASIA assessment training.
It is not immediately apparent how best to overcome the barriers associated with research capacity.
Investigators, especially research-active ones, are likely to routinely balance clinical activities with
existing and new clinical trials, whereas research and development (R&D) departments balance the
low cost-effectiveness associated with initiating rare disease trials with the cost-effectiveness of high
throughput or commercial studies. Ultimately, fiscal remunerations for adopting very rare disease trials
are likely to be required to facilitate the running of such trials with their associated barriers.
Considerations of the design of the study
Although the paucity of patient encounters and other operational barriers played a significant role in the
study under-recruiting, the contributory effect of the study design (in terms of eligibility criteria) to the
under-recruitment of the study cannot be overlooked. An analysis of site screening logs and feedback from
investigators indicated that the exclusion of ‘less severe’ patients (i.e. patients with an ASIA impairment
score of D) had some impact on the recruitment of patients into the study. Approximately 48% (n = 11/23)
of screened patients who did not meet the eligibility criteria did not do so as a result of their symptoms
being ‘mild’ or being assessed as having an ASIA impairment score of D. The study team recognised this
trend while the study was still active and considered amending the protocol to allow the inclusion of
patients assessed as having an ASIA impairment score of D or those whose symptoms were considered
to be ‘mild’ at the time of presentation. However, the primary end point of the study required patients
to have at least an ASIA impairment score of C to enable a two-grade improvement in this scale to
be observed.
The short window for recruitment (5 days from the date of first commencement of steroid therapy) was
the second factor that contributed to the low recruitment rate. Although it would have been easy to
remove this restriction, the early treatment paradigm was key to the study question and so was retained.
Achievements of the trial
The barriers described individually in the previous section and summarised in the timeline in Figure 3
collectively contributed to a formidable barrier that prevented the study from maintaining steady momentum
and recruiting to target. Nevertheless, despite the early termination of the study, the efforts involved in
trying to run this trial have resulted in two major hidden rewards. First, the study team has established a
network of investigators, including both adult and paediatric neurologists, who are ready to collaborate in
future studies and clinical trials in TM and other neuroinflammatory conditions. Second, set-up of the study
resulted in the provision of important training to local investigators with regard to evaluating patients with
TM. As such, we now have 15 paediatric and adult neurology centres that are more equipped to manage
adults and children with TM.
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Conclusion and recommendations
With 91% (n = 10/11) of the trial investigators (opinion leaders) surveyed agreeing that the study question
is important and should be a priority and 82% (n = 9/11) noting that the outcome of the study would
have changed how they treat TM patients, it is clear that our study question remains pertinent.
However, a future TM intervention trial would benefit from having robust, up-to-date information on the
incidence of TM and the distribution of the severity of patients presenting with TM. Multisource incidence
studies in both adults and children within the intended intervention study population would negate the
need to extrapolate data. Such a trial must also accommodate the evidence accrued on the spectrum of
the severity of TM within patients and thus an alternative outcome measure is required beyond the ASIA
Impairment Scale. Here, prospective studies recruiting patients to carefully evaluate the utility of other
available measures, such as the ASIA motor score, will be required. Importantly, the lessons learned from
this study are easily applicable to other very rare disorders.
Patient and public involvement
Patient and public representatives were actively involved in the design of the research, the management of
the research and the development of the participant information resources.
The TMS, Multiple Sclerosis Society and Guthy-Jackson Charitable Foundation were involved in the design
of the research. Two members from the TMS served on the TSC. Their involvement was crucial both in
finalising the research protocol and patient information sheet and in the overall direction that the study
took. Additionally, they provided a lay perspective on the probable public perceptions of the study and
offered key advice on how to maximise recruitment.
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Appendix 1 Dosing table for intravenous
immunoglobulin administration
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Appendix 2 Clinicoradiological diagnostic
algorithm
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Does the patient fit ALL the study inclusion criteria?
1. Aged ≥ 1 year
2. Clinical criteria for myelopathy
    EITHER TM – to include all of the following:
    • Sensory, motor or autonomic dysfunction attributable to spinal cord disease
    • Bilateral signs and/or symptoms (not necessarily symmetrical)
    • Clearly defined sensory level (except in young children aged < 5 years where this is difficult to evaluate)
    • Nadir between 4 hours and 21 days
    OR first-episode NMO – to include all of the following:
    • Optic neuritis
    • Acute myelitis
    • PLUS two of the following: brain MRI not consistent with MS; spinal cord MRI with T2 signal 
       abnormality over three vertebrae; AQP4 seropositive status
3. Patients may be recruited up to 5 days from the date of first commencing steroid therapy and, if definitively 
    known, this should not exceed 21 days from onset of symptoms
4. Gives consent/assent to take part in trial
Yes
Would the patient be excluded due to ANY of the exclusion criteria?
    • Contraindication to IVIG as stated in the product SmPC or receiving IVIG for other reasons
    • Previously known systemic autoimmune disease (e.g. SLE) or any evidence of systemic inflammation during
       current presentation (SLE, sarcoid, Behcet’s disease, Sjögren syndrome, MCTD)
    • Direct infectious aetiology (e.g. mycoplasma, TB, HTLV-1, HIV, HSV, enterovirus, VZV, EBV, CMV, HHV)
    • Previous episode of CNS inflammatory demyelination
    • Acute disseminated encephalomyelitis
    • Other causes of myelopathy not thought to be due to myelitis (e.g. nutritional, ischaemic, tumour)
    • Other diseases that would interfere with assessment of outcome measures
    • Pregnancy
    • Circumstances that would prevent follow-up for 12 months
Yes
Lumbar puncture for CSF pleocytosis OR raised IgG index
Sample taken for viral and bacterial culture
Does lumber puncture show CSF pleocytsis or raised IgG OR does MRI of spine show enhancement?
No
Yes
No
Age-appropriate patient information leaflet given and patient consent obtained?
Yes
Yes
No
Yes
ASIA impairment 
score of A–C?
If ASIA impairment score is 
D–E then monitor for 5 days,
as a deterioration to C–A 
would allow patient to 
enter pathwayEnter trial
Blood sample for biobanking
Non-compressive
myelopathy
Suspicion of first episode of myelopathy
 based on history and examination?
Urgent MRI of spine and brain 
(gadolinium contrast where possible)
Compressive myelopathy
 (e.g. tumour, haematoma)
• urgent surgical review and consider
   IVMP depending on aetiology
MRI of brain consistent with MS/ADEM
• alternative treatment pathway
Non-inflammatory myelopathy: 
vascular, radiation, 
neurodegenerative, metabolic, 
nutritional
• alternative treatment pathway
Suspicion of systemic inflammatory 
disorder or infectious aetiology?
• antibodies, ACE, viral and bacterial
   culture, complement
• alternative treatment pathway
Inflammatory myelopathy
Non-compressive myelopathy
FIGURE 4 Clinicoradiological diagnostic algorithm. ACE, angiotensin-converting enzyme; ADEM, acute disseminated
encephalomyelitis; CMV, cytomegalovirus; EBV, Epstein–Barr virus; HHV, human herpesvirus; HIV, human
immunodeficiency virus; HSV, herpes simplex virus; HTLV-1, human T-lymphotrophic virus 1; MCTD, mixed connective
tissue disease; SLE, systemic lupus erythematosus; TB, tuberculosis; VZV, varicella zoster virus.
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Appendix 3 Common side effects associated
with Intratect
Intratect can cause the following AEs, which may occur occasionally: chills, headache, fever, vomiting,allergic reactions, nausea, arthralgia, low blood pressure and mild back pain.
Rarely, human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases,
anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
Cases of reversible aseptic meningitis, isolated cases of reversible haemolytic anaemia/haemolysis and rare
cases of transient cutaneous reactions have also been observed with human normal immunoglobulin,
as well as an increase in serum creatinine level and/or acute renal failure.
Very rarely, thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism and
deep-vein thrombosis have been observed.
Other reported adverse reactions are:
l cardiac disorders – angina pectoris (very rare)
l general disorders and administration site conditions – rigors (very rare)
l immune system disorders – anaphylactic shock (very rare), hypersensitivity (very rare)
l investigations – blood pressure decreased (very rare)
l musculoskeletal and connective tissue disorders – back pain (very rare)
l respiratory, thoracic and mediastinal disorders – dyspnoea not otherwise specified (very rare)
l vascular disorders – shock (very rare).
The AEs reported above are expected in the sense that they are possible known side effects of the study
medication, but all reported instances of both SAEs and non-SAEs would have been reported in this study.
For a more detailed list of all reactions, see the Intratect SmPC [www.medicines.org.uk/emc/medicine/
23175/SPC/intratect/ (accessed 22 March 2017)].
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Appendix 4 Futility analysis plan
Proposal for an interim futility analysis
Introduction
Patients suffering from TM will be randomised equally between IVIG (the experimental arm, E) and steroids
(the control arm, C). The primary analysis will concern response to treatment, defined as an improvement
of two grades on a paralysis assessment scale over a 6-month period following treatment. It is anticipated
that the success rate on C will be pC = 0.5. The trial is to have 90% power to achieve significance at the
0.05 level (two-sided) if the success rate on E is pE = 0.75.
The final analysis of the study can be conducted in terms of the statistic χ2 = Σ(O – E)2/E, which can be
shown to be equal to Z2/V, where:
Z =
nCSE − nESC
n
=
nCnE
n
(p^E − p^C)
V =
nCnESF
n3
≈
nCnEp(1− p)
n
,
(1)
where nC and nE denote the numbers of patients and SC and SE denote the numbers of successes on C and
E, respectively, n = nC + nE, S = SC + SE, F = n – S, p^C = SC/nC p^E = SE/nE and p =
1
2 (pC + pE).
In fact, it will be concluded that E is significantly superior to C if C = Z/√V exceeds a suitable critical value k.
For equal randomisation, we have nC = nE = 0.5n and:
Z =
1
2
(SE− SC) and V =
SF
4n
. (2)
Sample size calculation
The SAS program sample size chi concerns a trial in which 152 patients are randomised, 76 to C and
76 to E. The probability that SC = i and SE = j is found for all i, j = 0,. . .,76. Thus, the probability of all 772
possible trial outcomes is found. The probability is found assuming that pC = pE = 0.5 and assuming that
pC = 0.5 and pE = 0.75. The possible outcomes are then arranged in descending order according to T
(denoting chi-squared test statistic), and cumulative probabilities of T being larger than or equal to every
possible value from 76 to –76 are computed. Reading the last row of the output for which χ = 1.95441
shows that P(χ ≥ 1.95441) is equal to 0.023555 when pC = pE = 0.5 and 0.90338 when pC = 0.5 and
pE = 0.75. Thus, the appropriate value for the critical value k is 1.95441. No suitable critical value can be
found for n = 150 and so the sample size should be n = 152.
This exact sample size calculation depends on the control success rate being precisely 0.5, although the
SAS program can be used to evaluate the decision rule – reject H0 if χ ≥ 1.95441 – under any other pair of
success rates. The sample size found is close to that obtained using Stata. Once the data are available, the
analysis will be based on Z, allowing for any departures from the intended sample size of 76 in each arm.
Additional patients to allow for potential dropouts can be added later.
An interim futility analysis
Suppose that an interim futility analysis is conducted after 52 patients have provided a response (26 in each
treatment arm). The trial is then terminated with the conclusion that E is no better than C if, based on these
52 patients, χ < 0. If the sample sizes are equal, this occurs if SE < SC. Otherwise, the trial proceeds to the
full sample size of 152, with 76 patients in each treatment arm, and the null hypothesis is rejected if
χ ≥ 1.95441.
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The SAS program two-stage chi concerns such a design. The probability that SC1 = i1, SC2 = i2, SE1 = j1 and
SE2 = j2 is found for all i1, j1 = 0,. . .,26 and all i2, j2 = 0,. . .,50, where SCr and SEr are the success totals in
the rth stage of the trial, r = 1, 2. Thus, the probability of every possible combination of outcomes in the
two stages of the trial is found. These are ordered by the final value of C and the results for which
P(χ ≥ k) = 0.025 under the null hypothesis and ≥ 0.90 under the alternative hypothesis are printed out.
This checking program takes a while to run and produces a lot of output. Line 5031 of the output
confirms that P(χ ≥ 1.95441) = 0.023555 when pC = pE = 0.5 and 0.90338 when pC = 0.5 and pE = 0.75.
The SAS program two-stage – interim – chi evaluates the design, but this time outcomes in which i1 > j1
are deleted. This corresponds to stopping corresponding trials for futility. In this case, P(χ ≥ 1.95441) =
0.022795 when pC = pE = 0.5 and 0.89462 when pC = 0.5 and pE = 0.75. This represents a very small loss
of power.
The SAS program two-stage – stage 1 – chi evaluates the properties of the first stage of the design.
It shows that the probability of abandoning the study at the interim analysis is 0.44494 when pC = pE = 0.5
and 0.020060 when pC = 0.5 and pE = 0.75. Thus, there is a good chance of stopping for futility when the
treatments are equivalent and a very small chance when the desired treatment effect is present.
Discussion
The calculations described in the previous sections indicate that a futility analysis conducted when
approximately one-third of the observations are available would be worthwhile and would have minimal
effect on the power. A final analysis conducted ignoring the interim analysis would be slightly conservative in
the sense of underestimating the advantage of E over C and reporting a p-value that was bigger (and thus
less significant) than any properly adjusted p-value. It would not appear to be worth making such an
adjustment.
If 152 patients are recruited over 2 years, then 52 patients would be recruited after 8.2 months.
The interim analysis would take place at 14.2 months, by which time a further 38 patients would have
been recruited. If the analysis was instant, there would be the potential to reduce the sample size by
62 patients, although this saving would be reduced because of continued recruitment during the analysis
period. If recruitment was to stretch beyond 2 years, the benefits of early stopping would increase.
The calculations performed are qualitative as the actual trial might depart from the model investigated here
in various small ways. Here, we declare E to be superior to C if χ ≥ 1.95441, although in practice the more
conventional criterion of χ ≥ 1.960 would probably be used. The calculations made here are exact, but only
for the null hypothesis pC= pE = 0.5 and not for the more general null hypothesis pC = pE. Calculations could
be rerun for the criterion χ ≥ 1.960; a slight increase in sample size might be needed to preserve power. In
practice, the sample sizes at the interim and final analyses might not be exactly 26 and 76 in each group
and they might not be equal in the two groups. The more general formula for C would then be used and
this is another reason for retaining the conventional cut-off value of 1.960.
Variations to the procedure, with different sample sizes at the interim and the null, can be evaluated and
properties under different pairs of values of pC and pE can be found. It would also be simple to investigate
a more stringent futility criterion, requiring C to exceed a value such as 0.5 or 1 to continue. This would
make the loss of power more substantial and open up the question of whether it should be compensated
for by an increase in sample size.
Notice that no opportunity for stopping at the interim analysis because of strong evidence of efficacy is
allowed. If that were allowed, then the properties of the method would need substantial re-evaluation and
conventional analyses would no longer be conservative.
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Appendix 5 Geographical distribution of those
diagnosed with transverse myelitis in 2015
FIGURE 5 Geographical distribution of those diagnosed with TM in 2015 (as per TMS data) in relation to the trial
sites (n= 51 of the 61 registered patients whose postal code allowed for mapping of their residence to local and
regional services). Each numbered black circle represents the number of individuals within the region on the map
reported (to the TMS) to have been diagnosed with TM in 2015. Each green circle represents a 25-mile radius
around a trial recruiting site and each red circle represents a 25-mile radius around a trial site that was targeted
for opening before the study was terminated.
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Appendix 6 Investigator responses to the
post-trial survey
1. The aim and overall objective of the study was clear (11 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
0 (0%) 0 (0%) 0 (0%)
8
6
4
2
0
1 2
Level of agreement with statement
4
7 (63.6%)
5
4 (36.4%)
N
u
m
b
er
 o
f 
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n
d
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ts
3
2. The study design was simple enough to understand (11 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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0
1 2
Level of agreement with statement
1 (9.1%)
4
7 (63.6%)
5
3 (27.3%)
3
0 (0%) 0 (0%)
3. All of the study procedures (including study visits at 3, 6 and 12 months post treatment) were in line
with our standard care for TM/NMO patients (11 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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5
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4a. The ASIA score was an appropriate measure to use (11 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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1
2 (18.2%)
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2 (18.2%)
3
Level of agreement with statement
4 (36.4%)
4
3 (27.3%)
5
0 (0%)
4b. What alternative would you have considered if any? (four responses)
5. The trial offered good treatment options for TM/NMO (10 responses) (1 = strongly disagree,
2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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6. The trial was sufficiently pragmatic (nine responses) (1 = strongly disagree, 2 = disagree, 3 = neither
agree nor disagree, 4 = agree, 5 = strongly agree).
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Level of agreement with statement
2 (22.2%)
4
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5
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7. The site was an appropriate choice for the trial (11 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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Investigator
1. I think addressing the study question is highly important and should be a priority (11 responses)
(1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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2. The outcome of this study would have changed how I treat my TM patients (11 responses) (1 = strongly
disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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Level of agreement with statement
1 (9.1%)
4
6 (54.5%)
5
3 (27.3%)
3. Within my daily workload, I believe I had enough time to allocate to activities that the study required
(both clinical and administrative) (11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither agree nor
disagree, 4 = agree, 5 = strongly agree).
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4. I generally find it difficult to participate in all kinds of clinical trials nowadays because of a lack of time
(11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly
agree).
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5. A study visit by a participant had (or would have had) an undesirable impact on my clinic (e.g.
significantly increasing the clinic time or time for administration of the clinic) (11 responses) (1 = strongly
disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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6. I generally find it difficult to find time for all study visits nowadays (11 responses) (1 = strongly disagree,
2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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7. What in your opinion was the single most important reason this trial failed (important, please answer)
(11 responses)
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8. What would you have changed about the study (important, please answer) (11 responses)
Study set-up and recruitment
1. I was actively involved in the site feasibility discussion before the study opened at my site (10 responses)
(1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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2. Set-up of the study felt complicated at times (10 responses) (1 = strongly disagree, 2 = disagree,
3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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3. All things considered, I think funding for sites for this study was not really adequate (11 responses)
(1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree).
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4. I found my interaction with our R&D department useful during the set-up and administration of this
study (if applicable) (11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree,
4 = agree, 5 = strongly agree).
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5. I was unable to recruit because (chose as many as applicable) (11 responses)
Other
Did not have time
Came to know late of cases
No cases came to my attention
Strict inclusion criteria
1 (9.1%)
0 (0%)
7 (63.6%)
5 (45.5%)
9 (81.8%)
0 1 2 3 4 5 6 7 8 9
Number of respondents
Other
1. I received as much assistance as needed from the study co-ordinating team (trial manager, sponsors,
etc.) (11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree,
5 = strongly agree).
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2. The study co-ordinating team could have done more to increase awareness of the study among other
clinicians or the potential patient population (11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither
agree nor disagree, 4 = agree, 5 = strongly agree).
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3. In future, I would be interested in collaborating with this team in designing and running another study
(11 responses) (1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly
agree).
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4. Any other comments? Please feel free to be critical, as we would like to learn from any mistakes made
in this study (five responses).
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